RxDoctor Payments Data

David Lofthus, MD

Cardiovascular Disease · Dallas, TXNPI 1851568968

Payments from drug & device makers

$870in general payments, 2019–2025

Across 42 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$240
  • Novartis$177
  • Medtronic$162
  • Novo Nordisk$71
  • E.r. Squibb & Sons, L.L.C.$62
  • Johnson & Johnson$36
  • plus $120 from 6 others

What the payments were for

  • Food & beverage$870100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$870 in reported general payments places this provider in the 20th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$332,644
Medicare patients
2,531
Services billed
6,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban680$680,970
EntrestoSacubitril/Valsartan172$224,213
XareltoRivaroxaban202$210,714
FarxigaDapagliflozin Propanediol100$97,502
Repatha SureclickEvolocumab77$69,318
JardianceEmpagliflozin54$60,501
MultaqDronedarone Hcl13$18,188
Ezetimibe554$13,188
Repatha SyringeEvolocumab14$10,917
NexletolBempedoic Acid20$10,111
Atorvastatin Calcium796$8,602
Praluent PenAlirocumab17$8,539
Flecainide Acetate158$6,929
Rosuvastatin Calcium461$6,875
Metoprolol Succinate497$6,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$240$680,970680 claims
NovartisEntresto$177$224,213172 claims
Johnson & JohnsonXarelto$36$210,714202 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →